52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Takeda & Novavax Announce Collaboration For Novavax' COVID-19 Vaccine Candidate In Japan
Novavax And Serum Institute Of India Announce Development And Commercial Collaboration
Novavax Announces $1.6 Billion Funding From Operation Warp Speed
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
Biotechnology & Drugs
21 Firstfield Rd
James Francis Young
Independent Chairman of the Board
Stanley C. Erck
President, Chief Executive Officer, Director
John J. Trizzino
Executive Vice President, Chief Business Officer, Chief Financial Officer and Treasurer
Gregory M. Glenn
President, Research and Development
Chief Human Resource Officer, Executive Vice President
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Takeda Pharmaceutical will manufacture and sell up to 250 million doses of Novavax Inc's COVID-19 vaccine candidate in Japan every year, the two companies said on Friday.
* NOVAVAX AND TAKEDA ANNOUNCE COLLABORATION FOR NOVAVAX' COVID-19 VACCINE CANDIDATE IN JAPAN
Novavax Inc said on Wednesday it has entered a supply and license agreement with the Serum Institute of India for the development and commercialization of its COVID-19 vaccine candidate.
Novavax Inc said on Tuesday its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus, according to initial data from a small, early-stage clinical trial, sending the company's shares up 10%.
Novavax Inc said on Tuesday its experimental COVID-19 vaccine produced antibodies against the novel coronavirus, according to initial data from a small, early-stage clinical trial.
Aug 4 - Novavax Inc said on Tuesday its experimental COVID-19 vaccine produced antibodies against the novel coronavirus and appears to be safe, according to initial data from a small, early-stage clinical trial.
One of the leading U.S. firms developing a coronavirus vaccine, Novavax Inc <NVAX.O>, has awarded executives stock options that could pay out tens of millions of dollars even if its efforts fail.
The U.S. government has awarded Novavax Inc $1.6 billion to cover testing and manufacturing of a potential vaccine for the novel coronavirus in the United States, with the aim of delivering 100 million doses by January.
(Updates with BARDA investment in Novavax vaccine, new grants to Regeneron's and AstraZeneca's therapies, updates development stage for AstraZeneca vaccine and diagnostics table) July 7 (Reuters) - As drugmakers race to develop vaccines, tests and therapies for the novel...
* NOVAVAX ANNOUNCES $1.6 BILLION FUNDING FROM OPERATION WARP SPEED
The U.S. government has awarded Novavax Inc $1.6 billion to cover testing, commercialization and manufacturing of a potential coronavirus vaccine in the United States, with the aim of delivering 100 million doses by January 2021.
* NOVAVAX INC - ON JUNE 24, CEPI ISSUED CO $76.0 MILLION OF $145.2 MILLION Source text: [https://bit.ly/2Nzbz0g] Further company coverage: (Reuters.Briefs@thomsonreuters.com)
* NOVAVAX ANNOUNCES ADDITIONS TO EXECUTIVE LEADERSHIP Source text for Eikon: Further company coverage:
* NOVAVAX APPOINTS BIOTECHNOLOGY VETERAN DAVID MOTT TO BOARD OF DIRECTORS
Novavax Inc said on Monday it would raise fresh capital through a $200 million preferred stock offering as it races to develop a vaccine for the new coronavirus, sending its shares up 10.5%.
Novavax Inc said on Thursday the U.S. Department of Defense (DoD) will give the late-stage biotech company up to $60 million to fund the manufacturing of its experimental COVID-19 vaccine.
* NOVAVAX AWARDED DEPARTMENT OF DEFENSE CONTRACT FOR COVID-19 VACCINE
Novavax Inc on Wednesday entered into a deal with contract drugmaker AGC Biologics to manufacture its experimental COVID-19 vaccine.
* NOVAVAX SELECTS AGC BIOLOGICS TO MANUFACTURE MATRIX-M™ ADJUVANT FOR NOVEL COVID-19 VACCINE Source text for Eikon: Further company coverage:
* NOVAVAX INC - ON MAY 27 ENTERED INTO A SHARE PURCHASE AGREEMENT Source text: (https://bit.ly/2Ajgsas) Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.